Down syndrome preleukemia and leukemia - PubMed (original) (raw)
Down syndrome preleukemia and leukemia
Kelly W Maloney et al. Pediatr Clin North Am. 2015 Feb.
Abstract
Children with Down syndrome (DS) and acute leukemias acute have unique biological, cytogenetic, and intrinsic factors that affect their treatment and outcome. Myeloid leukemia of Down syndrome (ML-DS) is associated with high event-free survival (EFS) rates and frequently preceded by a preleukemia condition, the transient abnormal hematopoiesis (TAM) present at birth. For acute lymphoblastic leukemia (ALL), their EFS and overall survival are poorer than non-DS ALL, it is important to enroll them on therapeutic trials, including relapse trials; investigate new agents that could potentially improve their leukemia-free survival; and strive to maximize the supportive care these patients need.
Keywords: B-ALL; Down syndrome; GATA1; Leukemia; Myeloid leukemia of Down syndrome; Preleukemia; Transient abnormal hematopoiesis/transient myeloproliferative disorder.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
- Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome.
Saida S, Watanabe K, Sato-Otsubo A, Terui K, Yoshida K, Okuno Y, Toki T, Wang R, Shiraishi Y, Miyano S, Kato I, Morishima T, Fujino H, Umeda K, Hiramatsu H, Adachi S, Ito E, Ogawa S, Ito M, Nakahata T, Heike T. Saida S, et al. Blood. 2013 May 23;121(21):4377-87. doi: 10.1182/blood-2012-12-474387. Epub 2013 Mar 12. Blood. 2013. PMID: 23482930 - Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.
Malinge S, Izraeli S, Crispino JD. Malinge S, et al. Blood. 2009 Mar 19;113(12):2619-28. doi: 10.1182/blood-2008-11-163501. Epub 2009 Jan 12. Blood. 2009. PMID: 19139078 Free PMC article. Review. - GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia.
Roberts I, Alford K, Hall G, Juban G, Richmond H, Norton A, Vallance G, Perkins K, Marchi E, McGowan S, Roy A, Cowan G, Anthony M, Gupta A, Ho J, Uthaya S, Curley A, Rasiah SV, Watts T, Nicholl R, Bedford-Russell A, Blumberg R, Thomas A, Gibson B, Halsey C, Lee PW, Godambe S, Sweeney C, Bhatnagar N, Goriely A, Campbell P, Vyas P; Oxford-Imperial Down Syndrome Cohort Study Group. Roberts I, et al. Blood. 2013 Dec 5;122(24):3908-17. doi: 10.1182/blood-2013-07-515148. Epub 2013 Sep 10. Blood. 2013. PMID: 24021668 Free PMC article. - Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD. Greene ME, et al. Blood Cells Mol Dis. 2003 Nov-Dec;31(3):351-6. doi: 10.1016/j.bcmd.2003.08.001. Blood Cells Mol Dis. 2003. PMID: 14636651 - Evolution of myeloid leukemia in children with Down syndrome.
Saida S. Saida S. Int J Hematol. 2016 Apr;103(4):365-72. doi: 10.1007/s12185-016-1959-5. Epub 2016 Feb 24. Int J Hematol. 2016. PMID: 26910243 Review.
Cited by
- Immunophenotypic markers for the evaluation of minimal/measurable residual disease in acute megakaryoblastic leukemia.
Pinto CM, Bertolucci CM, Severino AR, Dos Santos Tosi JF, Ikoma-Colturato MRV. Pinto CM, et al. Hematol Transfus Cell Ther. 2024 Oct-Dec;46(4):542-548. doi: 10.1016/j.htct.2023.09.2364. Epub 2023 Nov 17. Hematol Transfus Cell Ther. 2024. PMID: 38008596 Free PMC article. - First Reported Case of Atypical Meningioma in an Individual with Down Syndrome.
Vanderschelden R, Golshani K, Evans MG. Vanderschelden R, et al. Case Rep Neurol. 2022 Apr 4;14(1):191-196. doi: 10.1159/000523665. eCollection 2022 Jan-Apr. Case Rep Neurol. 2022. PMID: 35611359 Free PMC article. - Copy Number Changes and Allele Distribution Patterns of Chromosome 21 in B Cell Precursor Acute Lymphoblastic Leukemia.
Abbasi MR, Nebral K, Haslinger S, Inthal A, Zeitlhofer P, König M, Schinnerl D, Köhrer S, Strehl S, Panzer-Grümayer R, Mann G, Attarbaschi A, Haas OA. Abbasi MR, et al. Cancers (Basel). 2021 Sep 13;13(18):4597. doi: 10.3390/cancers13184597. Cancers (Basel). 2021. PMID: 34572826 Free PMC article. - Inhibition of cystathionine β-synthase promotes apoptosis and reduces cell proliferation in chronic myeloid leukemia.
Wang D, Yang H, Zhang Y, Hu R, Hu D, Wang Q, Liu Y, Liu M, Meng Z, Zhou W, Song W. Wang D, et al. Signal Transduct Target Ther. 2021 Feb 8;6(1):52. doi: 10.1038/s41392-020-00410-5. Signal Transduct Target Ther. 2021. PMID: 33558454 Free PMC article. - JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome.
Tuttle KD, Waugh KA, Araya P, Minter R, Orlicky DJ, Ludwig M, Andrysik Z, Burchill MA, Tamburini BAJ, Sempeck C, Smith K, Granrath R, Tracy D, Baxter J, Espinosa JM, Sullivan KD. Tuttle KD, et al. Cell Rep. 2020 Nov 17;33(7):108407. doi: 10.1016/j.celrep.2020.108407. Cell Rep. 2020. PMID: 33207208 Free PMC article.
MeSH terms
Grants and funding
- G1000729/MRC_/Medical Research Council/United Kingdom
- MC_UU_12009/11/MRC_/Medical Research Council/United Kingdom
- MC_UU_12009/14/MRC_/Medical Research Council/United Kingdom
- MR/L008963/1/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical